Semax — Wolverine Health

How it works

A synthetic heptapeptide based on the 4–10 fragment of ACTH, engineered to retain neurotrophic properties without hormonal activity. In animal models it increases BDNF and NGF, supports neurogenesis, and shows neuroprotective effects after ischemia. A registered medicine in Russia for stroke recovery and cognitive decline. The non-Russian clinical trial base is small — the neurotrophic mechanism is real, the human benefit in healthy people is not established.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review. Registered drug in Russia for stroke and cognitive impairment indications.
WADA status: Permitted in sport
Route: intranasal

Key studies

Nootropic peptides from the ACTH family — Kost et al.

Semax, a synthetic heptapeptide derived from the ACTH 4-10 fragment, retains neurotrophic properties without adrenocorticotropic activity and increases BDNF expression in rodent brain tissue.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on Semax

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where the access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

Peptide bioavailability: why oral, subcutaneous, and nasal routes have different evidence bases

WADA

The route a peptide gets dosed by changes its evidence base more than most readers realise. Oral, subcutaneous, and intranasal each ask different questions of the molecule. Here is why the route a study used often does not match the route the product is sold under.

The HPA axis and cognitive peptides: how selank and semax may modulate stress response

WADA

The HPA axis is the body's stress-response chain — hypothalamus, pituitary, adrenal cortex, cortisol. Two Russian-tradition peptides get sold for stress and cognition. Neither sits where the marketing implies. Here is what each actually engages.

Semax: cognitive enhancement claims and the evidence behind them

WADA

Semax is sold as a nootropic and was developed in Russia as a stroke treatment. Here's what the structural precision requires, what the mechanism shows in animals, and why Russian stroke evidence is not Western nootropic evidence.

Selank vs Semax: two Soviet-era peptides, two cognitive angles

Selank and Semax get sold side-by-side as cognitive performance peptides. Neither was built for that. Here is what the actual evidence shows, where the Russian-literature replication gap sits, and how the July 2026 FDA review splits the two peptides apart.

Semax: Neuroprotection and Cognitive Research on a Russian ACTH Analog

WADA

Science-journalism overview of Semax — the ACTH-derived heptapeptide studied for neuroprotection and cognitive enhancement, what preclinical and limited human data show, and its position on the PCAC July 2026 docket.